Augmenting Scientific Discovery and Research Infrastructure in the UAB Regional Biocontainment Laboratory (SEBLAB)

项目概要：目前的提案概述了一项战略计划，以实施新的 遏制措施内的技术，将推进NIAID的使命，以支持大流行病 第三类风险病原体的防备和生物医学研究。该提案重点 先进设备的实施，以推进体外（目标1），体内（目标2），和 高遏制病原体的分子研究（目标3），并寻求建立在 科学主任的诊断专业知识，以建立一个高遏制分子 能够快速应对未来新出现的流行病威胁的基础设施， 诊断测试开发和实际应用，用于患者护理和公共卫生 干预创新包括：1）第一个提案寻求获得尖端设备， 提高亚拉巴马大学伯明翰分校SEBLAB科学生产力，2）小说 在安全壳内使用蔡斯晶格光片显微镜，3）创新实施 超高分辨率计算机断层扫描和PET/SPECT功能， 由美国最大的TR 24回旋加速器（UAB）产生的放射性核素，用于非侵入性诊断 RGIII病原体的成像研究，4）创建执行生物能量分析的能力， 在SEBLAB进行单细胞测序，以及5）在安全壳内实施分子基础设施 实现快速诊断测试开发和验证， CLIA/CAP认证的临床和公共卫生实验室。鉴于目前的流行病， 未来的爆发，研究技术的快速进步，对UAB的投资 当前提案中概述的SEBLAB将转化为对大流行病的实际影响 做好准备，加速竞争激烈的基础生物医学和转化研究 提高我们对高风险生物武器的基本认识和生物防御能力的产出。 隔离病原体

Project Summary: The current proposal outlines a strategic plan to implement novel technologies within containment that will advance the NIAID mission to support pandemic preparedness and biomedical research on risk group III (RGIII) pathogens. This proposal focuses on the implementation of cutting edge equipment to advance in vitro (Aim1), in vivo (Aim2), and molecular investigation (Aim3) of high containment pathogens and also seeks to build upon the diagnostic expertise of the Scientific Director to establish a high containment molecular infrastructure capable of rapidly responding to future emerging pandemic threats with rapid diagnostic test development and real-world implementation for patient care and public health intervention. Innovations include: 1) First proposal seeking to acquire cutting edge equipment to increase scientific productivity at University of Alabama at Birmingham (UAB)’s SEBLAB, 2) Novel use of the Zeiss lattice light-sheet microscope within containment, 3) Innovative implementation of ultra-high resolution computed tomography and PET/SPECT capabilities enabling use of novel radionuclides generated by the nation’s largest TR24 cyclotron (UAB) for non-invasive diagnostic imaging research on RGIII pathogens, 4) Create the ability to perform bioenergetic analyses and single cell sequencing at SEBLAB, and 5) Implement molecular infrastructure within containment enabling rapid diagnostic test development and validation with a clear path to implementation in CLIA/CAP-accredited clinical and public health laboratories. Given the current pandemic, risks for future outbreaks, and rapid advancement of research technologies, investment in the UAB SEBLAB as outlined in the current proposal will translate into real-world impacts on pandemic preparedness and accelerate hyper-competitive basic biomedical and translational research output that advances our basic understanding and biodefense capabilities against high containment pathogens.